Pentraxin 3: A novel and independent prognostic marker in ischemic stroke

Atherosclerosis

Volumn 220, Issue 2, 2012, Pages 581-586

  Ryu, Wi Sun ^a   Kim, Chi Kyung ^a   Kim, Beom Joon ^a   Kim, Chulho ^a,b   Lee, Seung Hoon ^a   Yoon, Byung Woo ^a  

^a Seoul National University Hospital   (South Korea)

^b Hallym University   (South Korea)

Author keywords

Ischemic stroke; Mortality; Pentraxin 3

Indexed keywords

C REACTIVE PROTEIN; PENTRAXIN 3;

ADULT; ARTICLE; BRAIN ISCHEMIA; CLINICAL ARTICLE; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; SERUM AMYLOID P-COMPONENT; STROKE; TIME FACTORS;

EID: 84855915960     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.11.036     Document Type: Article

References (24)

1. Feigin V.L., Lawes C.M., Bennett D.A., Anderson C.S. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003, 2:43-53.
2. Song I.U., Kim J.S., Kim Y.I., et al. Relationship between high-sensitivity C-reactive protein and clinical functional outcome after acute ischemic stroke in a Korean population. Cerebrovasc Dis 2009, 28:545-550.
3. Abraha H.D., Butterworth R.J., Bath P.M., et al. Serum S-100 protein, relationship to clinical outcome in acute stroke. Ann Clin Biochem 1997, 34(Pt 4):366-370.
4. Katan M., Fluri F., Morgenthaler N.G., et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009, 66:799-808.
5. Topakian R., Haring H.P., Aichner F.T. Admission C-reactive protein as a predictor for stroke outcome among candidates for thrombolysis: decision adjourned. Stroke 2006, 37:2454. author reply 5-6.
6. Di Napoli M., Di Gianfilippo G., Sollecito A., Bocola V. C-reactive protein and outcome after first-ever ischemic stroke. Stroke 2000, 31:238-239.
7. Garlanda C., Bottazzi B., Bastone A., Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005, 23:337-366.
8. Bottazzi B., Vouret-Craviari V., Bastone A., et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 1997, 272:32817-32823.
9. Jenny N.S., Arnold A.M., Kuller L.H., Tracy R.P., Psaty B.M. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2009, 29:594-599.
10. Latini R., Maggioni A.P., Peri G., et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004, 110:2349-2354.
11. Inoue K., Sugiyama A., Reid P.C., et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007, 27:161-167.
12. Suzuki S., Takeishi Y., Niizeki T., et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008, 155:75-81.
13. Tong M., Carrero J.J., Qureshi A.R., et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2007, 2:889-897.
14. Jee S.H., Sull J.W., Park J., et al. Body-mass index and mortality in Korean men and women. N Engl J Med 2006, 355:779-787.
15. Ryu W.S., Lee S.H., Kim C.K., Kim B.J., Yoon B.W. Effects of low serum triglyceride on stroke mortality: a prospective follow-up study. Atherosclerosis 2010, 212:299-304.
16. Yun K.E., Park H.S., Song Y.M., Cho S.I. Increases in body mass index over a 7-year period and risk of cause-specific mortality in Korean men. Int J Epidemiol 2010, 39:520-528.
17. Peri G., Introna M., Corradi D., et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000, 102:636-641.
18. Dubin R., Shlipak M., Li Y., et al. Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis. Nephrol Dial Transplant 2010, 26:1903-1908.
19. Mantovani A., Garlanda C., Doni A., Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol 2008, 28:1-13.
20. Norata G.D., Garlanda C., Catapano A.L. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med 2010, 20:35-40.
21. Rolph M.S., Zimmer S., Bottazzi B., et al. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002, 22:e10-e14.
22. Klouche M., Peri G., Knabbe C., et al. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 2004, 175:221-228.
23. Kotooka N., Inoue T., Aoki S., et al. Prognostic value of pentraxin 3 in patients with chronic heart failure. Int J Cardiol 2008, 130:19-22.
24. Akerfeldt T., Larsson A. Pentraxin 3 increase is much less pronounced than C-reactive protein increase after surgical procedures. Inflammation 2010, 34:367-370.